EP3765854A1 - Marqueurs de la synaptopathie dans une maladie neurodégénérative - Google Patents

Marqueurs de la synaptopathie dans une maladie neurodégénérative

Info

Publication number
EP3765854A1
EP3765854A1 EP19709749.6A EP19709749A EP3765854A1 EP 3765854 A1 EP3765854 A1 EP 3765854A1 EP 19709749 A EP19709749 A EP 19709749A EP 3765854 A1 EP3765854 A1 EP 3765854A1
Authority
EP
European Patent Office
Prior art keywords
level
neurexin
synaptopathy
individual
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19709749.6A
Other languages
German (de)
English (en)
Inventor
Olivia BELBIN
Alberto LLEÓ BISA
Alejandro BAYÉS PUIG
Juan FORTEA ORMAECHEA
Daniel ALCOLEA RODRÍGUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Original Assignee
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau filed Critical Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Publication of EP3765854A1 publication Critical patent/EP3765854A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés in vitro pour le diagnostic et/ou le pronostic de la synaptopathie et/ou de la neurodégénérescence chez un individu, pour décider s'il faut initier une intervention thérapeutique, et pour surveiller l'efficacité de l'intervention thérapeutique, sur la base de la détermination du niveau d'expression de produit de VAMP-2 et/ou de la syntaxine-1. Avantageusement, ces marqueurs permettent la détection précoce de la synaptopathie dans des maladies telles que la maladie d'Alzheimer.
EP19709749.6A 2018-03-16 2019-03-15 Marqueurs de la synaptopathie dans une maladie neurodégénérative Pending EP3765854A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382175 2018-03-16
PCT/EP2019/056535 WO2019175379A1 (fr) 2018-03-16 2019-03-15 Marqueurs de la synaptopathie dans une maladie neurodégénérative

Publications (1)

Publication Number Publication Date
EP3765854A1 true EP3765854A1 (fr) 2021-01-20

Family

ID=61768234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19709749.6A Pending EP3765854A1 (fr) 2018-03-16 2019-03-15 Marqueurs de la synaptopathie dans une maladie neurodégénérative

Country Status (2)

Country Link
EP (1) EP3765854A1 (fr)
WO (1) WO2019175379A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214324A1 (fr) * 2022-05-04 2023-11-09 Universita' Degli Studi Di Milano Méthode de diagnostic

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160327572A1 (en) * 2014-01-06 2016-11-10 Children's Medical Center Corporation Biomarkers for Dementia and Dementia Related Neurological Disorders

Also Published As

Publication number Publication date
WO2019175379A1 (fr) 2019-09-19

Similar Documents

Publication Publication Date Title
Blennow et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
US10670613B2 (en) Antibody array for measuring a panel of amyloids
Marksteiner et al. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study
EP3728567B1 (fr) Méthode d'évaluation d'une synucléinopathie
JP7480180B2 (ja) アルファ－シヌクレインアッセイ
Marcucci et al. Biomarkers and their implications in Alzheimer’s disease: a literature review
EP3765854A1 (fr) Marqueurs de la synaptopathie dans une maladie neurodégénérative
US20230349906A1 (en) Kinases as biomarkers for neurodegenerative conditions
Hampel et al. Biomarkers in blood and cerebrospinal fluid
Lu et al. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment
Steinerman et al. Laboratory biomarkers in Alzheimer’s disease
WO2014016373A1 (fr) Taux de protéines du c9orf72 pour le diagnostic d'une maladie neurodégénérative
US9618522B2 (en) Diagnostic testing in dementia and methods related thereto
Vrillon Clinical study of novel fluid biomarkers in Alzheimer's disease and other neurodegenerative disorders
WO2023206347A1 (fr) Produit épissé ddit4l en tant que marqueur de diagnostic pour la maladie d'alzheimer
Marcucci et al. Biomarkers and Their Implications in Alzheimer’s Disease: A
CA3222315A1 (fr) Indices de diagnostic pour des affections neurodegeneratives
Pantel et al. Blood and cerebrospinal fluid biological markers for Alzheimer’s disease
JP2024063160A (ja) アルファ－シヌクレインアッセイ
Schooneboom et al. Cerebrospinal fluid markers for the diagnosis of Alzheimer’s disease
JP2023551542A (ja) アルツハイマー病の非侵襲的評価
Tokuda et al. Alpha-Synuclein in Cerebrospinal Fluid

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230908

B565 Issuance of search results under rule 164(2) epc

Effective date: 20230908

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20230905BHEP